A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome)

The purpose of the study is to gain experience of a patient management pathway in patients with heart failure including protocolized medications from an integrated device diagnostic-based risk stratification algorithm based on the data collected by the Reveal LINQ device. The study will evaluate use of the LINQ Heart Failure Risk Status algorithm to guide patient care in subjects with class II or III congestive heart failure.

OCEAN(a) Outcome- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a).

Multi-center, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.

ANALOG: Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients with Chronic Heart Failure

The primary objective of this study is to assess the safety and efficacy of the VITARIA™ system when added to stable, guideline-directed medical therapy for patients with heart failure and reduced heart muscle function.

The purpose of this clinical investigation is to develop valid scientific evidence for the safety and effectiveness of the BAROSTIM NEO System delivered by the BATwire Implant Kit (BATwire Kit) in subjects with heart failure.

Core is a double blind, placebo controlled phase 3 study of Akcea-APOCIII-LRX administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). The study will evaluate the efficacy of the agent as compared to placebo in the percent change in fasting triglycerides (TG) from Baseline in a population of patients with fasting triglycerides of >500 mg/dl.

This study is a multicenter, randomized, double-blind , placebo-controlled trial to evaluate the effect of in-hospital initiation of Dapagloflozin on clinical outcomes in patients with heart failure who have been stabilized during hospitalization for acute heart failure.